This year’s meeting, in Boston May 16-20, has brought in a record number of accepted abstracts – 1,126 – in all areas of endocrinology. The lion’s share focuses on diabetes, thyroid disease, and bone disease. Most will be presented in Poster Viewing and Judging sessions at 10:00 a.m on Thursday for young investigators and during a poster viewing and wine and cheese reception from 4:30 p.m. to 6:30 p.m. on Friday for senior investigators.
Of note, the mother lode of clinical trials, retrospective analyses, and registry studies will be shown at the senior investigator competition on Friday evening.
That viewing session will include two post hoc analyses of data from the global SUSTAIN trial program in the investigational GLP-1 receptor agonist semaglutide. The first, Abstract 245, examines whether reductions in body weight and HbA1c differed between elderly and younger patients in. The second, Abstract 298, is an analysis of SUSTAIN 1-5 and 7, looking at semaglutide’s effectiveness across racial and ethnic subgroups.
Another large trial, CANVAS, will be represented in two abstracts in this Friday session. In CANVAS, canagliflozin for primary prevention didn’t significantly reduce cardiovascular events in patients with at-risk type 2 diabetes, but it did so convincingly in a secondary prevention population. Outcomes by age group will be presented in Abstract 233, while those by changes in HbA1c and use of antihyperglycemic drugs will be presented in Abstract 262.
Other studies of interest in this viewing session include but are not limited to a comparison of the effects of hypnosis and certified diabetes educators on weight loss and changes in HbA1c levels (Abstract 602) and an investigation into whether the anabolic agent teriparatide can aid in foot bone remodeling in patients with Charcot neuroarthropathy (Abstract 225).